



RECEIPT

PATENT

Attorney Docket No. 28967 34140A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alitalo *et al.*

Serial No.: 09 534,376

Filed: March 24, 2000

For: VASCULAR ENDOTHELIAL  
GROWTH FACTOR C (VEGF-C)  
PROTEIN AND GENE  
MUTANTS THEREOF, AND  
USES THEREOF

Group Art Unit: 1632

Examiner: To be assigned.

) I hereby certify that this paper is being  
) deposited with the United States Postal  
) Service as first class mail, postage prepaid,  
) in an envelope addressed to: Assistant  
) Commissioner for Patents, Washington, DC  
) 20231 on this date:

June 7, 2000

David A. Gass, Esq.

Reg. No. 38,153

Attorney for Applicants

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

Sir:

Attached hereto are copies of a filing receipt issued by the Patent Office, the cover sheet filed with the patent application, and page 1 of the patent application as filed. It will be apparent from the patent application that the filing receipt contains an incomplete priority claim. It will be apparent from the cover sheet that the inventors' residences were provided. The applicants respectfully request issuance of a new filing receipt that identifies the inventors' residences and that identifies all of the priority applications, dating back to 1994. Because the application claims priority back to 1994, it is entitled to special status for examination purposes.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

By

David A. Gass  
Registration No. 38,153  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

June 7, 2000



## FILING RECEIPT



\*OC000000005130072\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/534,376	03/24/2000	1632	633	28967/34140A	16	39	6

Marshall O'Toole Gerstein Murray & B...  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, IL 60606-6402

**RECEIVED**  
MAY 26 2000  
MARSHALL O'TOOLE

Date Mailed: 05/22/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

**Applicant(s)**

Kari Alitalo, Residence Not Provided;  
Vladimir Joukov, Residence Not Provided;

**Continuing Data as Claimed by Applicant**

THIS APPLICATION IS A CON OF 09/355,700 11/05/1999  
WHICH IS A 371 OF PCT/US98/01973 02/02/1998  
AND A CIP OF 08/795,430 02/05/1997

**Foreign Applications**

If Required, Foreign Filing License Granted 05/19/2000

**\*\* SMALL ENTITY \*\*****Title**

Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof

**Preliminary Class**


435

Data entry by : HARDY, EUGENIA

Team : OIPE

Date: 05/22/2000





**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The check number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

28967/34140A

JOINT INVENTORS



"EXPRESS MAIL" mailing label

No. EM 099900625 US.

Date of Deposit: March 24, 2000


I hereby certify that this paper (or fee) is being deposited with the United States Postal Service

"EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on

the date indicated above and is addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231

  
Richard Zimmermann

APPLICATION FOR  
UNITED STATES LETTERS PATENT

**SPECIFICATION**

---

TO ALL WHOM IT MAY CONCERN:

Be it known that we, KARI ALITALO, a citizen of Finland, residing at Nyyrikintie 4A, 02100 Espoo, Finland, and VLADIMIR JOUKOV, a citizen of Russia, residing at 51 Massachusetts Ave., Apt. 1F, Boston 02115, and State of Massachusetts have invented a new and useful "VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF", of which the following is a specification.



## **VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF**

This application is a continuation of U.S. Patent Application No. 09/355,700, which is a 35 USC §371 U.S. National Stage filing of International  
5 Application No. PCT/US98/01973, filed February 2, 1998. This application also is a continuation-in-part of United States Patent Application Serial No. 08/795,430, filed February 5, 1997. This patent application also is a continuation-in-part of International Patent Application PCT/FI96/00427, filed August 01, 1996; and a continuation-in-part of United States Patent Application Serial No. 08/671,573, filed June 28, 1996; and a  
10 continuation-in-part of United States Patent Application Serial Number 08/601,132, filed February 14, 1996; and a continuation-in-part of United States Patent Application Serial Number 08/585,895, filed January 12, 1996; and a continuation-in-part of United States Patent Application Serial Number 08/510,133, filed August 1, 1995; and a continuation-in-part of United States Patent Application Serial Number 08/340,011, filed November  
15 14, 1994, now U.S. Patent No. 5,776,755.

### **FIELD OF THE INVENTION**

The present invention generally relates to the field of genetic engineering and more particularly to growth factors for endothelial cells and growth factor genes.

### **BACKGROUND OF THE INVENTION**

20 Developmental growth, the remodeling and regeneration of adult tissues, as well as solid tumor growth, can only occur when accompanied by blood vessel formation. Angioblasts and hematopoietic precursor cells differentiate from the mesoderm and form the blood islands of the yolk sac and the primary vascular system of the embryo. The development of blood vessels from these early (*in situ*) differentiating  
25 endothelial cells is termed vasculogenesis. Major embryonic blood vessels are believed to arise via vasculogenesis, whereas the formation of the rest of the vascular tree is